← All candidates
56 insider filings on record.
56 filings on record.
TBPHTheravance Biopharma, Inc.
NasdaqGM · Healthcare · $884.70M
$17.04
+0.06% · Sep 15
56 insider filings on record.
None of them an open-market buy in the last year.
Price · 1Y · daily● 16 sells
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$884.70M
Float
25.9M
50% public
Short % float
Pro
Price / profit
16.4
Price / future profit
13.4
Price / sales
8.5
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
1 filingnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
51 more transactions on Pro →Context
Wall St
$17.67 avg target
+3.7% vs today · 3 analysts · consensus Hold
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
3 of 4 quarters beat
Q1 '26$0.01 act−$0.08
Q4 '25$0.06 act+$0.05
Q3 '25$0.04 act+$0.09
Q2 '25−$0.08 act+$0.04
Coverage
Theravance Stock Down 3% After Zymeworks Announces BuyoutZacks · 06-30Zymeworks agrees to buy Theravance Biopharma for $929mPharmaceutical Technology · 06-30Zymeworks To Buy Theravance Biopharma In $929M Deal – A Look At What This Deal Means For TBPH ShareholdersStocktwits · 06-29Zymeworks to Buy Theravance for Lung Disease Drug. Both Stocks Are Sliding.Barrons.com · 06-29
The file stays open
56 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice